Association of SGLT2 inhibitors with suicidality, all-cause mortality, and hospitalization in bipolar disorder: A cohort study of 1.23 million adults - PubMed
18 hours ago
- #Bipolar Disorder
- #Mental Health Outcomes
- #SGLT2 Inhibitors
- The study analyzed data from 1,230,821 adults with bipolar disorder, including 36,092 SGLT2 inhibitor users and 1,194,729 non-users over five years.
- SGLT2 inhibitor exposure was associated with reduced risks: suicidality (aHR 0.75), all-cause mortality (aHR 0.55), and hospitalization (aHR 0.71), with consistent benefits across demographic and clinical subgroups.
- After propensity score matching (31,001 pairs), SGLT2i users showed higher rates of suicidality-free survival (94.51% vs. 93.56%), overall survival (88.99% vs. 79.57%), and hospitalization-free survival (72.39% vs. 66.72%), all statistically significant.
- The findings suggest SGLT2 inhibitors may improve psychiatric and survival outcomes in bipolar disorder, warranting prospective randomized controlled trials for further validation.